Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background.
Nurphoto | Nurphoto | Getty Images
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.
The company’s stock was down 5.52% at 11:10 a.m. London time.
This breaking news story is being updated.
